UroGen Pharma
UroGen is a company committed to elevating options for people living with urological cancers through breakthrough technology and transformative therapies.
Last updated September 1, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
UroGen is a pharmaceutical company focused on urological cancers. It has a portfolio of FDA-approved treatments leveraging its innovative RTGel technology, including Jelmyto and Zusduri. The company's pipeline is focused on innovative treatments for uro-oncology patients. UroGen is committed to conducting business with high ethical standards and has adopted a Comprehensive Compliance Program.
History
UroGen is a company committed to elevating options for people living with urological cancers. It has a portfolio of FDA-approved treatments leveraging its innovative RTGel technology, including Jelmyto and Zusduri. The company's pipeline is focused on innovative treatments for uro-oncology patients. UroGen has a Comprehensive Compliance Program and is led by President and CEO Liz Barrett.
Products and positioning
Jelmyto
FDA-approved treatment leveraging RTGel technology
Zusduri
FDA-approved treatment leveraging RTGel technology
Recent events
Reported
UroGen lowers 2026 JELMYTO revenue guidance[6]
UroGen updated its full-year 2026 net product revenue guidance for JELMYTO to approximately $90 million, down from its prior range of $97 million to $101 million.
Reported
UroGen reports third-quarter 2026 financial results[6]
UroGen Pharma Ltd. announced its third-quarter 2026 financial results, reporting total revenue of $89.0 million and a net loss of $1.5 million.
Reported
FDA approves Jelmyto for low-grade upper tract urothelial cancer[7]
The FDA approved mitomycin gel, marketed as Jelmyto by UroGen Pharma, for the treatment of low-grade upper tract urothelial cancer.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/urogen-pharma · Editorial policy · How profiles are compiled